Adjuvance Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 15
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $1.47M
Latest Deal Amount
  • Investors
  • 6

Adjuvance General Information

Description

Developer of a biopharmaceutical platform designed to improve health and save lives through development in vaccine adjuvant. The company's platform is based on SAPONEX products that are critical components to many vaccines for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy, enabling patients to improve their immunity system.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 1225 L Street
  • Suite 600
  • Lincoln, NE 68508
  • United States
+1 (402) 000-0000

Adjuvance Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Adjuvance Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 19-May-2020 $1.47M 000.00 Completed Pre-Clinical Trials
3. Later Stage VC (Series A1) 29-Jan-2020 0000 000.00 0000 Completed Pre-Clinical Trials
2. Seed Round 29-Aug-2019 $4.6M $4.6M Completed Pre-Clinical Trials
1. Grant 31-May-2015 $1.5M Completed Startup
To view Adjuvance’s complete valuation and funding history, request access »

Adjuvance Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Adjuvance’s complete cap table history, request access »

Adjuvance Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a biopharmaceutical platform designed to improve health and save lives through development in vaccine adjuv
Drug Discovery
Lincoln, NE
15 As of 2020
000.00
0000000000 000.00

0000000

ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor i
0000000000000
Emeryville, CA
000 As of 0000
00000
000000000 00000

0000000

iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
0000000000000
Gaithersburg, MD
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adjuvance Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dynavax Technologies Corporation Emeryville, CA 000 00000 000000000 00000
0000000 Corporation Gaithersburg, MD 000 00000 000000000 00000
000000000000000 00 Corporation Saint-Amand-Les-Eaux, France
You’re viewing 3 of 3 competitors. Get the full list »

Adjuvance Executive Team (10)

Name Title Board Seat Contact Info
Tyler Martin Chief Executive Officer, President & Chairman
Stephan Schulze Chief Financial Officer
Patrick Giljum Chief Technology Officer
Patrick Frenchick Ph.D Chief Scientific Officer
Sean Bennett Chief Medical Officer
You’re viewing 5 of 10 executive team members. Get the full list »

Adjuvance Board Members (10)

Name Representing Role Since
Isaac Cheng MD Self Board Member 000 0000
Kenneth Kelley Adjuvance Board Member 000 0000
Margaret Liu Adjuvance Board Member 000 0000
Stephen Dilly Ph.D Self Board Member 000 0000
Tyler Martin Adjuvance Chief Executive Officer, President & Chairman 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Adjuvance Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adjuvance Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institute Of Allergy and Infectious Diseases Government 000 0000 000000 0
5Y Capital Venture Capital Minority 000 0000 000000 0
Flying Point Industries Venture Capital Minority 000 0000 000000 0
Invest Nebraska Accelerator/Incubator Minority 000 0000 000000 0
Mont Alto Capital Family Office Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »